Most linked-to pages
From Glioblastoma Treatments
Jump to navigationJump to search
Showing below up to 43 results in range #151 to #193.
- Varies; can include fatigue, headache, localized reactions at infusion site (2 links)
- Varies; earlier phases showed median overall survival up to 38 months in phase I trial participants. (2 links)
- While initial phase III trial results in newly diagnosed GBM were disappointing, the ReACT trial for recurrent GBM suggests potential benefits, particularly when combined with bevacizumab (2 links)
- Wilms Tumor 1 (WT1) Peptide Vaccine (2 links)
- Wilms Tumor Peptide Vaccine (2 links)
- Category:Other Chemotherapy and Cancer Drugs (2 links)
- Property:Has Usefulness Explanation (2 links)
- 1 out of 16 patients was alive after one year. (2 links)
- 6 out of 14 patients were alive after one year (2 links)
- Not explicitly detailed in recent reviews (2 links)
- Recent meta-analyses suggest potential for improving cancer treatment outcomes (2 links)
- Isotretinoin (Accutane) (2 links)
- Disulfiram (Antabuse) (2 links)
- Methadone (D,L-methadone) (2 links)
- Proton Pump Inhibitors (e.g., Lansoprazole, Nexium) (2 links)
- 3.5 (2 links)
- Median survival with standard treatment: 17.4 months (2 links)
- Not directly specified; improvements noted in selected patient analyses (2 links)
- Post-hoc analysis with at least six months of Valcyte use: median survival of 24 months, 4-year survival of 27% (2 links)
- Valganciclovir (Valcyte) (2 links)
- Valproic Acid/Sodium Valproate (Depakote) (2 links)
- Combination of Repurposed Drugs plus Temodar (2 links)
- Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival (2 links)
- The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone (2 links)
- Not applicable; research has not extensively measured progression-free survival in cancer patients (2 links)
- Preclinical studies and early clinical trials (2 links)
- Not specifically documented; focus on overall survival improvements (2 links)
- Celebrex (Celecoxib) and Other NSAIDs (2 links)
- Phase III (2 links)
- Chronotherapy with TMZ could significantly extend survival times, particularly for patients with MGMT methylated tumors. (2 links)
- Early clinical trials show promising results in improving overall survival and progression-free survival in various cancers, including potential benefits for GBM. Ongoing trials will provide more definitive data. (2 links)
- Hyperthermia has shown potential in enhancing the effectiveness of radiation and chemotherapy, improving overall survival and progression-free survival rates in glioblastoma patients. (2 links)
- Metronomic low-dose TMZ may offer a viable option for patients with recurrent GBM, providing a balance between efficacy and reduced toxicity compared to standard dosing. Further research is ongoing to confirm these benefits. (2 links)
- Shows a clinically meaningful extension of survival in both newly diagnosed and recurrent GBM patients. Offers fresh hope by potentially improving outcomes in a challenging treatment landscape. (2 links)
- Shows promise based on significant improvements in overall survival and disease-free survival in high-risk AML patients; ongoing research needed to fully establish efficacy in other cancers (2 links)
- The vaccine shows promise, especially in extending progression-free survival in newly diagnosed GBM. It offers a novel approach by leveraging the patient's immune system, potentially improving outcomes in a disease with few effective treatments. (2 links)
- 3 (awaiting research) (2 links)
- 3 - Under investigation (2 links)
- MN-166 (Ibudilast) (2 links)
- Gamma Knife Radiosurgery (GKRS) for GBM (2 links)
- Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence (2 links)
- Phase 3 (2 links)
- Preclinical studies (2 links)
